Inclusion Criteria:

          -  Histologically confirmed pediatric mature B-cell non-Hodgkin lymphoma (B-cell NHL)
             including the following subtypes; Burkitt lymphoma/ Burkitt leukemia (BL), diffuse
             large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), gray zone
             lymphoma (GZL), and follicular lymphoma (FL) Note: Patients with B-cell NHL associated
             with Nijmegen breakage syndrome will be allowed.

          -  Patients <25 years of age and weighing at least 6 kg at the time of screening

          -  Patients who have relapsed after one or more prior therapies (can include allogeneic
             and autologous hematopoietic stem cell transplant) or are primary refractory (have not
             achieved a CR or PR after the first line of therapy)

          -  Measurable disease by radiological criteria in all patients at the time of screening.
             Patients with Burkitt leukemia who don't meet radiological criteria must have bone
             marrow involvement of >25% by local assessment of bone marrow aspirate and/or biopsy.

          -  Karnofsky (age ≥16 years) or Lansky (age <16 years) performance status ≥60.

          -  Adequate bone marrow reserve without transfusions (transfusion >2 weeks prior to
             laboratory assessment is allowed) defined as:

               1. Absolute neutrophil count (ANC) >1000/mm3

               2. Platelets ≥50000//mm3

               3. Hemoglobin ≥8.0 g/dl

          -  Adequate organ function defined as:

               1. a serum creatinine (sCR) based on gender/age as follows: Maximum Serum Creatinine
                  (mg/dL) Age Male Female

                  1 to <2 years 0.6 0.6 2 to <6 years 0.8 0.8 6 to <10 years 1.0 1.0 10 to <13
                  years 1.2 1.2 13 to <16 years 1.5 1.4

                  ≥16 years 1.7 1.4

               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5 times the
                  upper limit of normal (ULN) for age

               3. Total bilirubin <2 mg/dL (for Gilbert's Syndrome patients total bilirubin <4
                  mg/dL)

               4. Adequate pulmonary function

             i. Oxygen saturation of >91% on room air ii. No or mild dyspnea (≤Grade 1)

          -  Must have a leukapheresis material of non-mobilized cells accepted for manufacturing.

        Exclusion Criteria:

          -  Prior gene therapy or engineered T cell therapy.

          -  Prior treatment with any anti-CD19 therapy.

          -  Allogeneic hematopoietic stem cell transplant (HSCT) <3 months prior to screening and
             ≤4 months prior to infusion.

          -  Presence of grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD)
             in patients who received prior allogeneic HSCT.

          -  Prior diagnosis of malignancy other than study indication, and not disease free for 5
             years.

          -  Clinically significant active infection confirmed by clinical evidence, imaging, or
             positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA, etc.)

          -  Presence of active hepatitis B or C as indicated by serology.

          -  Human Immunodeficiency Virus (HIV) positive test.

          -  Active neurological autoimmune or inflammatory disorders not related to B cell NHL
             (eg: Guillain-Barre syndrome, Amyotrophic Lateral Sclerosis)

          -  Active central nervous system (CNS) involvement by malignancy.

          -  Patients with B-cell NHL in the context of post-transplant lymphoproliferative
             disorders (PTLD) associated lymphomas.

        Other protocol-defined inclusion/exclusion criteria may apply.